| Name | Savolitinib |
| Description | Savolitinib (Volitinib) (AZD-6094) is an effective, selective, and orally bioavailable c-Met inhibitor (IC50s: 5 nM/3 nM for c-Met/p-Met). |
| In vitro | Savolitinib selectively binds to and inhibits the activation of c-Met in an ATP-competitive manner, and disrupts c-Met signal transduction pathways [1,2]. |
| In vivo | In a U87MG subcutaneous xenograft model, Savolitinib (1-10.0 mg/kg; oral administration; daily; for 21 days; athymic nude mice) demonstrates dose-dependent tumor growth inhibition. In addition, none of the mice in the dosing groups exhibits body weight loss during the experiment [1]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (5.79 mM), Sonication is recommended. DMSO : 32 mg/mL (92.66 mM), Sonication is recommended.
|
| Keywords | Savolitinib | Inhibitor | inhibit | HMPL504 | HMPL 504 | HGFR | c-Met/HGFR | cMet/HGFR | c-Met | cMet | AZD6094 | AZD 6094 |
| Inhibitors Related | (S)-Afatinib | (Z)-Semaxinib | Decanoic Acid | Afatinib Dimaleate | L-Ascorbic acid 2-phosphate trisodium | Crizotinib | 7-Methoxy-1-tetralone | Tepotinib | Afatinib | Cabozantinib S-malate | Bacitracin Zinc | Capmatinib |
| Related Compound Libraries | Highly Selective Inhibitor Library | Failed Clinical Trials Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Kinase Inhibitor Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |